Author Archives for Adeline Chauvigné

BioMAdvanced Diagnostics: agreement with Nantes University Hospital to use anonymized clinical data from 300 kidney transplant patients

📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article

Rédigé par Adeline Chauvigné, le 2022-07-01

BioMAdvanced Diagnostics: agreement with Nantes University Hospital to use anonymized clinical data from 300 kidney transplant patients

📢 [Key Milestone] BioMAdvanced Diagnostics enters an agreement with Nantes’ University Hospital to analyze anonymized clinical data from 300 kidney... View Article

Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article

Rédigé par Adeline Chauvigné, le 2022-06-28

Naobios delivers Flugen Inc’s M2SR influenza vaccine candidate for upcoming clinical trials

Naobios’ development work and GMP manufacturing of vaccine clinical batches enables FluGen to conduct its 2022 clinical trials in the... View Article

Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain

Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article

Rédigé par Adeline Chauvigné, le 2022-06-28

Apellis expands R&D collaboration with Affilogic to develop targeted complement therapies for delivery into the brain

Apellis Pharmaceuticals and Affilogic announced that the companies have expanded their research and development (R&D) collaboration, which was initially formed... View Article

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article

Rédigé par Adeline Chauvigné, le 2022-07-12

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe

Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001 Valneva , a specialty vaccine company, today announced... View Article

Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article

Rédigé par Adeline Chauvigné, le 2022-07-11

Valneva receives marketing authorization in Europe for inactivated whole-virus COVID-19 vaccine VLA2001

VLA2001 becomes the first COVID-19 vaccine to receive a standard marketing authorization in Europe Valneva, a specialty vaccine company, today... View Article

Valneva announces settlement agreement with the UK Government

Valneva, a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the... View Article

Rédigé par Adeline Chauvigné, le 2022-06-16

Valneva announces settlement agreement with the UK Government

Valneva, a specialty vaccine company, today announced that it has entered into a settlement agreement with the Government of the... View Article

OSE Immunotherapeutics announces collaboration with Microsoft

OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech... View Article

Rédigé par Adeline Chauvigné, le 2022-06-16

OSE Immunotherapeutics announces collaboration with Microsoft

OSE selected by Microsoft France to join the “Biotech Scaler Program” launched during “Viva Technology”, the European Startup and Tech... View Article

Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA

Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article

Rédigé par Adeline Chauvigné, le 2022-06-28

Safety and efficacy results of LIS1, a new induction treatment in organ transplantation by the French biotech XENOTHERA

Results from the clinical trial of LIS1, XENOTHERA’s polyclonal glyco-humanised antibody and induction immunosuppressant in solid organ transplantation, were presented... View Article

Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb

Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence... View Article

Rédigé par Adeline Chauvigné, le 2022-06-08

Owkin announces multi-year clinical data science strategic collaboration with Bristol Myers Squibb

Owkin announced that it has entered into a multi-year, strategic collaboration with Bristol Myers Squibb to apply Owkin’s Artificial Intelligence... View Article

EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 vaccine candidate

Valneva, a specialty vaccine company, confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization... View Article

Rédigé par Adeline Chauvigné, le 2022-05-30

EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 vaccine candidate

Valneva, a specialty vaccine company, confirmed that the European Medicines Agency (“EMA”) has accepted the filing of a marketing authorization... View Article